Pankaj Kumar

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Topics

Aortic Dissection

Breast Cancer Cells

Top Venues

Nanomedicine (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Bharti Mangla, Priya Mittal, Pankaj Kumar, Shamama Javed, Waquar Ahsan, Geeta Aggarwal
Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ . Nanomedicine (London, England) 19 (10) (2024)
Bharti Mangla, Priya Mittal, Pankaj Kumar, Shamama Javed, Waquar Ahsan, Geeta Aggarwal
Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ . Nanomedicine (London, England) 19 (10) (2024)
Bharti Mangla, Priya Mittal, Pankaj Kumar, Shamama Javed, Waquar Ahsan, Geeta Aggarwal
Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ . Nanomedicine (London, England) 19 (10) (2024)
Bharti Mangla, Pankaj Kumar, Zuber Ahamad, Shamama Javed, Waquar Ahsan, Geeta Aggarwal
Development and evaluation of berberine-loaded bigel for the treatment of hyperpigmentation on B16F10 melanoma cell line. Nanomedicine (London, England) (2024)
Bharti Mangla, Priya Mittal, Pankaj Kumar, Shamama Javed, Waquar Ahsan, Geeta Aggarwal
Development of erlotinib-loaded nanotransferosomal gel for the topical treatment of ductal carcinoma in situ . Nanomedicine (London, England) (2024)
Pankaj Kumar, Bharti Mangla, Shamama Javed, Waquar Ahsan, Geeta Aggarwal
Amelioration of the therapeutic potential of gefitinib against breast cancer using nanostructured lipid carriers. Nanomedicine (London, England) (2023)
Bharti Mangla, Yub Raj Neupane, Archu Singh, Pankaj Kumar, Sadat Shafi, Kanchan Kohli
Lipid-nanopotentiated combinatorial delivery of tamoxifen and sulforaphane: ex vivo, in vivo and toxicity studies. Nanomedicine (London, England) 15 (26) (2020)